Viatris Inc. (VTRS)
Price:
16.07 USD
( + 0.12 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Amneal Pharmaceuticals, Inc.
VALUE SCORE:
5
2nd position
Neurocrine Biosciences, Inc.
VALUE SCORE:
9
The best
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
NEWS
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
prnewswire.com
2026-02-25 06:59:00FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics
zacks.com
2026-02-23 10:16:50Evaluate the expected performance of Viatris (VTRS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
What's in Store for These 5 Medical Companies This Earnings Season?
zacks.com
2026-02-23 10:11:13IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
seekingalpha.com
2026-02-20 08:52:20Upcoming launches between 2026–2027, including fast-acting meloxicam, cenerimod, and selatogrel, could support a return to mid-single-digit sales growth and improve margins. With FCF yield above 10% and solid deleveraging capacity, Viatris combines deep-value characteristics with optionality from targeted acquisitions and shareholder returns. VTRS also anticipates $500 million in net cost savings by 2028, with reinvestment supporting higher-value brands.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
zacks.com
2026-02-19 11:01:44Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
globenewswire.com
2026-02-19 09:02:00NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET.
Dividend Income: Lanny's December 2025 Summary
seekingalpha.com
2026-02-17 06:23:00In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, dividend increases created $4.44 in additional passive dividend income.
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
prnewswire.com
2026-02-03 16:34:00PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m.
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
prnewswire.com
2026-02-03 08:30:00Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026.
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
prnewswire.com
2026-01-20 06:59:00Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-13 16:46:02Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Burney U.S. Factor Rotation ETF Buys Shares of Viatris Inc (NAS:VTRS)
gurufocus.com
2026-01-13 14:44:00Summary Burney U.S. Factor Rotation ETF initiated a new position in Viatris Inc by purchasing 222,793 shares, bringing its total holdings to 222,793 shares a
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
prnewswire.com
2026-01-08 09:05:00PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies.
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com
2026-01-06 13:01:08Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
globenewswire.com
2026-01-06 09:00:00Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
zacks.com
2025-12-19 13:20:33VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
prnewswire.com
2026-02-25 06:59:00FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics
zacks.com
2026-02-23 10:16:50Evaluate the expected performance of Viatris (VTRS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
What's in Store for These 5 Medical Companies This Earnings Season?
zacks.com
2026-02-23 10:11:13IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
seekingalpha.com
2026-02-20 08:52:20Upcoming launches between 2026–2027, including fast-acting meloxicam, cenerimod, and selatogrel, could support a return to mid-single-digit sales growth and improve margins. With FCF yield above 10% and solid deleveraging capacity, Viatris combines deep-value characteristics with optionality from targeted acquisitions and shareholder returns. VTRS also anticipates $500 million in net cost savings by 2028, with reinvestment supporting higher-value brands.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
zacks.com
2026-02-19 11:01:44Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
globenewswire.com
2026-02-19 09:02:00NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET.
Dividend Income: Lanny's December 2025 Summary
seekingalpha.com
2026-02-17 06:23:00In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, dividend increases created $4.44 in additional passive dividend income.
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
prnewswire.com
2026-02-03 16:34:00PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m.
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
prnewswire.com
2026-02-03 08:30:00Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026.
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
prnewswire.com
2026-01-20 06:59:00Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-13 16:46:02Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Burney U.S. Factor Rotation ETF Buys Shares of Viatris Inc (NAS:VTRS)
gurufocus.com
2026-01-13 14:44:00Summary Burney U.S. Factor Rotation ETF initiated a new position in Viatris Inc by purchasing 222,793 shares, bringing its total holdings to 222,793 shares a
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
prnewswire.com
2026-01-08 09:05:00PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies.
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com
2026-01-06 13:01:08Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
globenewswire.com
2026-01-06 09:00:00Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
zacks.com
2025-12-19 13:20:33VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.